Skip to main content
. 2012 Dec 10;2012:354145. doi: 10.1155/2012/354145

Table 3.

Difference in adjusted mean change of MENQOL and its subscales score between interventions and placebo group*.

Subscales Time/weeks PSY + CHM versus Placebo PSY versus Placebo CHM versus Placebo CHM + PSY versus PSY CHM versus CHM + PSY CHM versus PSY
Difference in mean change
(95% CI)		 P value P adjust Difference in mean change
(95% CI)		 P value P adjust Difference in mean change
(95% CI)		 P value P adjust Difference in mean change
(95% CI)		 P value P adjust Difference in mean change
(95% CI)		 P value P adjust Difference in mean change
(95% CI)		 P value P adjust
  12 −1.08 0.6044 1 1.49 0.4704 1 −1.89 0.3551 1 −2.57 0.2171 1 −0.81 0.6933 1 −3.39 0.0982 1
  (−8.14–5.98) (−5.52–8.51) (−8.82–5.04) (−9.64–4.49) (−7.79–6.17) (−10.32–3.54)
Vasomotor 24 −1.74 0.4188 1 1.32 0.5413 1 1.92 0.3625 1 −3.06 0.1561 1 3.66 0.0816 1 0.59 0.7780 1
(−9.04–5.56) (−6.01–8.66) (−5.21–9.05) (−10.37–4.25) (−3.45–10.76) (−6.55–7.74)
  Over all time points 0.21 0.8851 1 1.98 0.1628 0.9771 0.48 0.7322 1 −1.78 0.2114 1 0.27 0.8456 1 −1.51 0.2808 1
  (−3.56–3.97) (−1.78–5.74) (−3.22–4.17) (−5.54–1.99) (−3.43–3.97) (−5.2–2.19)
  12 0.95 0.7936 1 4.85 0.1825 1 −3.57 0.3188 1 −3.89 0.2860 1 −4.53 0.2086 1 −8.42 0.0192*  1
  (−11.41–13.32) (−7.47–17.17) (−15.73–8.58) (−16.26–8.47) (−16.73–7.67) (−20.58–3.73)
Psychosocial 24 6.06 0.0992 1 3.88 0.2919 1 −0.24 0.9471 1 2.18 0.5527 1 −6.3 0.0799 1 −4.12 0.2530 1
(−6.38–18.5) (−8.59–16.34) (−12.42–11.94) (−10.27–14.64) (−18.47–5.87) (−16.31–8.08)
  Over all time points 4.35 0.1517 0.9103 5.01 0.0984 0.5907 −2.07 0.4876 1 −0.67 0.8261 1 −6.42 0.0318 0.1910 −7.08 0.0179 0.1073
  (−3.68–12.38) (−3.01–13.04) (−9.97–5.83) (−8.69–7.36) (−14.32–1.48) (−14.98–0.81)
  12 −8.63 0.1967 1 −5.65 0.3962 1 −11.03 0.0936 1 −2.98 0.6552 1 −2.39 0.7163 1 −5.38 0.4129 1
  (−31.28–14.02) (−28.21–16.91) (−33.28–11.23) (−25.63–19.66) (−24.74–19.95) (−27.63–16.88)
Physical 24 7.73 0.2595 1 5.57 0.4184 1 −3 0.6542 1 2.17 0.7523 1 −10.74 0.1092 1 −8.57 0.2025 1
(−15.5–30.96) (−17.75–28.88) (−25.74–19.73) (−21.1–25.43) (−33.43–11.96) (−31.35–14.21)
  Over all time points −1.4 0.7987 1 0.62 0.9101 1 −5.38 0.3193 1 −2.02 0.713 1 −3.98 0.4611 1 −6 0.2669 1
  (−15.94–13.14) (−13.93–15.17) (−19.69–8.93) (−16.57–12.53) (−18.29–10.33) (−20.31–8.31)
  12 0.14 0.9489 1 −1.46 0.5146 1 −2.88 0.1921 1 1.6 0.4736 1 −3.02 0.1704 1 −1.42 0.5181 1
  (−7.46–7.75) (−9.05–6.13) (−10.36–4.6) (−5.98–9.19) (−10.49–4.45) (−8.87–6.03)
Sexual 24 1.02 0.6568 1 0.61 0.7915 1 −1.45 0.5175 1 0.41 0.8578 1 −2.47 0.2683 1 −2.06 0.3578 1
(−6.74–8.78) (−7.18–8.4) (−9.05–6.15) (−7.34–8.15) (−10.02–5.09) (−9.65–5.53)
  Over all time points 0.63 0.7404 1 −0.3 0.8753 1 −1.87 0.3176 1 0.93 0.6239 1 −2.51 0.1795 1 −1.58 0.399 1
  (−4.41–5.68) (−5.35–4.75) (−6.84–3.09) (−4.09–5.96) (−7.44–2.43) (−6.52–3.37)
  12 −8.18 0.4723 1 −1.1 0.9225 1 −18.85 0.0924 1 −7.08 0.5327 1 −10.67 0.3397 1 −17.74 0.1118 1
  (−46.75–30.39) (−39.59–37.38) (−56.76–19.06) (−45.52–31.37) (−48.54–27.2) (−55.52–20.04)
QOL 24 13.88 0.2295 1 11.58 0.3175 1 −2.08 0.8540 1 2.3 0.8415 1 −15.96 0.1565 1 −13.66 0.2266 1
(−25.25–53.02) (−27.67–50.82) (−40.42–36.26) (−36.76–41.37) (−54.12–22.19) (−51.93–24.61)
  Over all time points 4.07 0.6629 1 7.14 0.4444 1 −8.58 0.3502 1 −3.07 0.7408 1 −12.64 0.1668 1 −15.72 0.0861 0.5165
  (−20.64–28.77) (−17.58–31.86) (−32.89–15.73) (−27.69–21.54) (−36.84–11.56) (−39.93–8.5)

∗ P < 0.05.

∗All analyses were conducted on the data adjusted for age (continuous), body mass index (kg/m2, continuous), menopausal status (menopause transition versus postmenopausal). Estimates of difference in mean change from baseline versus placebo, along with P values and 95% CIs, from mixed-model analysis that used data from baseline and all follow-up time points (total, n = 424 for adjusted analyses).